A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms
Blocking specific immune checkpoints restores natural killer cells' ability to attack a deadly leukemia subtype in lab tests, opening a targeted treatment path.
This epi-transcriptomic study identified a novel 49-gene stemness program and a specific TIGIT-PVRIG-DNAM1/CD112 immunological axis dysfunction in monosomy 7 myeloid neoplasms (AML/MDS), finding that CD112 overexpression on leukemic cells suppresses NK cell activity via upregulated TIGIT/PVRIG. Blocking TIGIT and PVRIG receptors restored autologous NK cytolysis against monosomy 7 leukemic cells ex vivo, suggesting checkpoint inhibitor therapy as a new strategy for this poor-prognosis cytogenetic subset.
What the study was
- Study design
- Epi-transcriptomic profiling study with ex vivo NK cytotoxicity model and in vivo validation in primary AML patient cells
- Population
- Patients with myeloid neoplasms (AML/MDS) harboring monosomy 7 (affects 10–20% of myeloid neoplasms, associated with poor prognosis)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Signal Transduction and Targeted Therapy
Why it surfaced
First description of a targetable immunological axis (TIGIT/PVRIG/CD112) in monosomy 7 myeloid neoplasms — a poor-prognosis cytogenetic change affecting 10–20% of myeloid neoplasms with no current targeted therapy. Published in Signal Transduct Target Ther (IF ~40). Epi-transcriptomic + ex vivo validation demonstrates actionable NK checkpoint blockade strategy. Raises triage score for novelty and design rigor.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.